Dermatology Ms. Ella Brookes is a Clinical Outcome Assessment Lead specializing in dermatology and immuno-inflammatory diseases, with strong expertise in patient-centered evidence generation. Her education includes an MSc in Public Health from the London School of Hygiene and Tropical Medicine and a BSc in Psychology from Kingston University, supported by clinical and teaching certifications. Professionally, Ms. Ella Brookes leads COA strategy at Sanofi, managing global regulatory, HTA, and clinical development programs across dermatology indications. Her research interests focus on patient-reported outcomes, disease modeling, and digital health tools. Her research skills include qualitative and quantitative methods, COA development, and regulatory engagement. Ms. Ella Brookes has earned professional recognition through leadership in global collaborations, and she concludes as a key contributor advancing evidence-based dermatology and patient-focused clinical innovation.
Citation Metrics (Scopus)
500
400
300
200
100
0
.
–
🟦 Citations 🟥 Documents 🟩 h-index
View Scopus Profile
Featured Publications
Improvement and Maintenance of Clinical Outcome Assessments in Atopic Dermatitis with Amlitelimab
– Journal of the European Academy of Dermatology and Venereology, 2025
Validation of a Scoring Algorithm for the Clinician-Reported Outcome Tool “Prurigo Activity and Severity (PAS)”
– Journal of the European Academy of Dermatology and Venereology, 2024
Estimating Meaningful Change Thresholds for Skin Pain, Sleep, and Quality of Life in Prurigo Nodularis
– Journal of the European Academy of Dermatology and Venereology, 2024
Heterogeneity of Patient Preferences for Benefits and Risks of Antiplatelet Therapies
– Pharmacoepidemiology and Drug Safety, 2020
Fatigue and Pain Remain Prominent and Impactful in Patients with Systemic Lupus Erythematosus
– Cross-Sectional Survey, United States, 2020
Patient-Centered Benefit-Risk Analysis of Transcatheter Aortic Valve Replacement
– F1000Research, 2019
Patient Experiences with Obstructive and Non-Obstructive Hypertrophic Cardiomyopathy
– Conceptual Model of Symptoms and Quality of Life, 2020